The leading source of reliable cardiology information for practitioners and trainees worldwide, Braunwald’s Heart Disease, 13th Edition, remains the most trusted reference in the field. Written and edited by global experts, this award-winning, two-volume text offers outstanding coverage of new drugs, new guidelines, more powerful imaging modalities, and recent developments in precision medicine that continue to advance the practice of cardiovascular medicine and improve patients’ quality of life. This unparalleled multimedia reference is an essential resource for today’s cardiologists, cardiology fellows, and those studying for certification or recertification.
1. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. Contributors - p. vi 8. Contributors: Guideline summaries - p. xix 9. Preface to the thirteenth edition - p. xxiii 10. Preface to the first edition - p. xxiv 11. Video contents - p. xxx 12. Braunwald’s heart disease family of books - p. xxxiv 13. List of Illustrations - p. xxxvii 14. List of Tables - p. xxxviii 15. PART I. Foundations of Cardiovascular Medicine - p. xxxviii 16. 1. Cardiovascular disease: Past, present, and future - p. 1 17. 2. Global burden of cardiovascular disease - p. 14 18. 3. Impact of climate change and the environment on cardiovascular health - p. 31 19. 4. Clinical trials in cardiovascular medicine - p. 43 20. 5. Clinical decision-making in cardiology - p. 56 21. 6. Impact of health care policy on quality, outcomes, and equity in cardiovascular disease - p. 66 22. PART II. Personalized Approaches to Cardiovascular Disease - p. 74 23. 7. Applications of genetics to cardiovascular medicine - p. 75 24. 8. Principles of drug therapeutics, pharmacogenomics, and biologics - p. 90 25. 9. Biomarkers and use in precision m edicine - p. 99 26. 10. Artificial intelligence in cardiovascular medicine - p. 106 27. PART III. Evaluation of the Patient - p. 118 28. 11. History, physical examination, and the virtual visit - p. 119 29. 12. Electrocardiography - p. 138 30. 13. Exercise physiology and exercise testing - p. 171 31. 14. Echocardiography - p. 189 32. Principles of ultrasound and instrumentation - p. 190 33. Standard adult transthoracic echocardiographic examination - p. 194 34. Transesophageal echocardiography - p. 203 35. Three-dimensional echocardiography - p. 204 36. Ultrasound-enhancing agents - p. 205 37. Echocardiography and multimodality cardiac imaging - p. 206 38. Assessment of cardiac conditions: Myocardial infarction - p. 209 39. Cardiomyopathies and heart failure - p. 214 40. Stress echocardiography - p. 218 41. Valvular heart disease (see Part VIII) - p. 220 42. Pericardial disease (see Chapter 86) - p. 233 43. Diseases of the aorta (see Chapter 39) - p. 237 44. Pulmonary embolism (see Chapter 79) - p. 241 45. Pulmonary hypertension (see Chapter 80) - p. 243 46. Infective endocarditis (see Chapter 76) - p. 244 47. Systemic diseases and echocardiography - p. 246 48. Cardiac masses (see Chapter 94) - p. 247 49. Adult congenital heart disease (see Chapter 87) - p. 250 50. Transcatheter interventions (see Chapters 70 and 74) - p. 255 51. Future directions - p. 257 52. References - p. 260 53. 15. Chest radiography in cardiovascular disease - p. 262 54. 16. Nuclear cardiology - p. 271 55. 17. Cardiovascular magnetic resonance imaging - p. 307 56. 18. Cardiac computed tomography - p. 329 57. 19. Coronary angiography and intravascular imaging - p. 361 58. 20. Invasive hemodynamic diagnosis of cardiac disease - p. 384 59. 21. Anesthesia and noncardiac surgery in patients with heart disease - p. 409 60. PART IV. Preventive Cardiology - p. 424 61. 22. The vascular biology of atherosclerosis - p. 425 62. 23. Primary prevention of cardiovascular disease - p. 442 63. 24. Systemic hypertension: Mechanisms, diagnosis, and treatment - p. 471 64. 25. Lipoprotein disorders and cardiovascular disease - p. 502 65. 26. Cardiovascular effects of tobacco and nicotine products - p. 517 66. 27. Nutrition and cardiovascular and metabolic diseases - p. 524 67. 28. Obesity and cardiovascular health - p. 539 68. 29. Diabetes and the cardiovascular system - p. 551 69. 30. Comprehensive cardiac rehabilitation - p. 578 70. 31. Integrative approaches to the management of patients with heart disease - p. 583 71. PART V. Atherosclerotic Cardiovascular Disease - p. 588 72. 32. Approach to the patient with chest pain - p. 589 73. 33. Coronary blood flow and myocardial ischemia - p. 600 74. 34. ST-elevation myocardial infarction pathophysiology and clinical evolution - p. 627 75. 35. ST-elevation myocardial infarction: Management - p. 650 76. Limitation of infarct size - p. 651 77. Prehospital management - p. 652 78. Management in the emergency department - p. 653 79. Reperfusion therapy - p. 656 80. Anticoagulant and antiplatelet therapy - p. 661 81. Hospital management - p. 666 82. Hemodynamic disturbances - p. 671 83. Arrhythmias - p. 686 84. Other complications - p. 691 85. Convalescence, discharge, and postmyocardial infarction care - p. 693 86. Timing of hospital discharge after myocardial infarction - p. 693 87. Counseling - p. 693 88. Risk stratification after st-elevation myocardial infarction - p. 693 89. Assessment at hospital discharge - p. 693 90. Prophylactic antiarrhythmic therapy - p. 694 91. Secondary prevention after acute myocardial infarction - p. 694 92. Future perspectives and emerging therapies - p. 699 93. Guideline Highlights: STEMI Management - p. 699 94. References - p. 699.e6 95. References - p. 699.e6 96. 36. Non–ST elevation acute coronary syndromes - p. 700 97. 37. Stable ischemic heart disease - p. 725 98. Magnitude of the problem - p. 725 99. Stable angina pectoris - p. 726 100. Evaluation - p. 728 101. Medical management - p. 736.e2 102. Revascularization approaches in stable ischemic heart disease - p. 751 103. Other manifestations of coronary artery disease - p. 760 104. Future perspectives - p. 763 105. References - p. 764 106. 38. Percutaneous coronary intervention - p. 768 107. 39. Diseases of the aorta - p. 789 108. Normal aorta - p. 789 109. Aortic aneurysms - p. 791 110. Aortic dissection - p. 802 111. Classification - p. 802 112. Cause and pathogenesis - p. 802 113. Clinical manifestations - p. 804 114. Diagnostic techniques - p. 806 115. Selecting an imaging modality - p. 807 116. Integrated diagnostic evaluation and management algorithms - p. 808 117. Long-term management and follow-up - p. 812 118. Aortic dissection variants - p. 813 119. Aortoarteritis syndromes - p. 815 120. Primary tumors of the aorta - p. 815 121. Key messages and future perspectives for the diagnosis and treatment of aortic diseases - p. 817.e1 122. Aortic Disease* - p. 817.e1 123. Pregnancy in patients with aortopathy - p. 817.e13 124. Physical activity and quality of life - p. 817.e16 125. References - p. 817.e16 126. References - p. 817.e16 127. References - p. 817.e16 128. 40. Peripheral artery diseases - p. 818 129. 41. Treatment of noncoronary obstructive vascular disease - p. 840 130. 42. Prevention and management of ischemic stroke - p. 851 131. PART VI. Arrhythmias, Sudden Death, and Syncope - p. 868 132. 43. Approach to the patient with cardiac arrhythmias - p. 869 133. 44. Mechanisms of cardiac arrhythmias - p. 886 134. 45. Genetics of cardiac arrhythmias - p. 912 135. 46. Therapy for cardiac arrhythmias - p. 931 136. 47. Supraventricular tachycardias - p. 969 137. 48. Atrial fibrillation - p. 996 138. 49. Ventricular arrhythmias - p. 1012 139. 50. Bradyarrhythmias and atrioventricular block - p. 1036 140. 51. Pacemakers, conduction system pacing, cardiac resynchronization therapy, and implantable cardioverter-defibrillators - p. 1046 141. 52. Cardiac arrest and sudden cardiac death - p. 1076 142. 53. Hypotension and syncope - p. 1111 143. PART VII. Heart Failure - p. 1122 144. 54. Mechanisms of cardiac contraction and relaxation - p. 1123 145. 55. Pathophysiology of heart failure - p. 1147 146. 56. Clinical assessment of heart failure - p. 1167 147. 57. Diagnosis and management of decompensated heart failure - p. 1180 148. 58. Management of heart failure patients with reduced ejection fraction - p. 1208 149. 59. Heart failure with preserved or mildly reduced ejection fraction - p. 1239 150. 60. The dilated, restrictive, and infiltrative cardiomyopathies - p. 1266 151. 61. Cardiac amyloidosis - p. 1287 152. 62. Hypertrophic cardiomyopathy - p. 1298 153. 63. Myocarditis - p. 1313 154. 64. Cardio-oncology - p. 1328 155. 65. Devices for monitoring and managing heart failure - p. 1343 156. 66. Mechanical circulatory support - p. 1358 157. 67. Cardiac transplantation - p. 1370 158. PART VIII. Diseases of the Heart Valves - p. 1382 159. 68. Aortic valve stenosis - p. 1383 160. 69. Aortic regurgitation - p. 1404 161. 70. Transcatheter aortic valve replacement - p. 1415 162. 71. Mitral stenosis - p. 1428 163. 72. Mitral regurgitation - p. 1439 164. 73. Tricuspid, pulmonic, and multivalvular disease - p. 1457 165. 74. Transcatheter therapies for mitral and tricuspid valvular heart disease - p. 1468 166. 75. Prosthetic heart valves - p. 1479 167. 76. Infective endocarditis - p. 1490 168. 77. Rheumatic fever - p. 1503 169. PART IX. Diseases of the Pericardium and Pulmonary Vascular Bed - p. 1512 170. 78. Pericardial diseases - p. 1513 171. 79. Pulmonary embolism and deep vein thrombosis - p. 1533 172. 80. Pulmonary hypertension - p. 1557 173. 81. Sleep-disordered breathing and cardiac disease - p. 1580 174. PART X. Cardiovascular Disease in Select Populations - p. 1588 175. 82. Endemic and pandemic viral illnesses and cardiovascular disease: Influenza and COVID-19 - p. 1589 176. 83. Cardiovascular abnormalities in HIV-infected individuals - p. 1607 177. 84. Exercise and sports cardiology - p. 1620 178. 85. Cardiovascular disease in women - p. 1629 179. 86. Pregnancy and heart disease - p. 1643 180. 87. Congenital heart disease in the adolescent and adult - p. 1667 181. 88. Heart disease in various populations - p. 1710 182. 89. Cardiovascular disease in older adults - p. 1717 183. 90. Cardiovascular effects of drugs and toxins - p. 1739 184. PART XI. Cardiovascular Disease and Disorders of Other Systems - p. 1748 185. 91. Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease - p. 1749 186. 92. Endocrine disorders and cardiovascular disease - p. 1774 187. 93. Rheumatic diseases and the cardiovascular system - p. 1794 188. 94. Tumors affecting the cardiovascular system - p. 1815 189. 95. Psychiatric and psychosocial aspects of cardiovascular disease - p. 1827 190. 96. Neuromuscular disorders and cardiovascular disease - p. 1839 191. 97. Interface between kidney, metabolic, and cardiovascular diseases - p. 1858 192. 98. Cardiovascular manifestations of autonomic disorders - p. 1879 193. Disclosure index - p. DI-1 194. Index - p. I-1
The leading source of reliable cardiology information for practitioners and trainees worldwide, Braunwald’s Heart Disease, 13th Edition, remains the most trusted reference in the field. Written and edited by global experts, this award-winning, two-volume text offers outstanding coverage of new drugs, new guidelines, more powerful imaging modalities, and recent developments in precision medicine that continue to advance the practice of cardiovascular medicine and improve patients’ quality of life. This unparalleled multimedia reference is an essential resource for today’s cardiologists, cardiology fellows, and those studying for certification or recertification.
1. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Dedication - p. v 7. Contributors - p. vi 8. Contributors: Guideline summaries - p. xix 9. Preface to the thirteenth edition - p. xxiii 10. Preface to the first edition - p. xxiv 11. Video contents - p. xxx 12. Braunwald’s heart disease family of books - p. xxxiv 13. List of Illustrations - p. xxxvii 14. List of Tables - p. xxxviii 15. PART I. Foundations of Cardiovascular Medicine - p. xxxviii 16. 1. Cardiovascular disease: Past, present, and future - p. 1 17. 2. Global burden of cardiovascular disease - p. 14 18. 3. Impact of climate change and the environment on cardiovascular health - p. 31 19. 4. Clinical trials in cardiovascular medicine - p. 43 20. 5. Clinical decision-making in cardiology - p. 56 21. 6. Impact of health care policy on quality, outcomes, and equity in cardiovascular disease - p. 66 22. PART II. Personalized Approaches to Cardiovascular Disease - p. 74 23. 7. Applications of genetics to cardiovascular medicine - p. 75 24. 8. Principles of drug therapeutics, pharmacogenomics, and biologics - p. 90 25. 9. Biomarkers and use in precision m edicine - p. 99 26. 10. Artificial intelligence in cardiovascular medicine - p. 106 27. PART III. Evaluation of the Patient - p. 118 28. 11. History, physical examination, and the virtual visit - p. 119 29. 12. Electrocardiography - p. 138 30. 13. Exercise physiology and exercise testing - p. 171 31. 14. Echocardiography - p. 189 32. Principles of ultrasound and instrumentation - p. 190 33. Standard adult transthoracic echocardiographic examination - p. 194 34. Transesophageal echocardiography - p. 203 35. Three-dimensional echocardiography - p. 204 36. Ultrasound-enhancing agents - p. 205 37. Echocardiography and multimodality cardiac imaging - p. 206 38. Assessment of cardiac conditions: Myocardial infarction - p. 209 39. Cardiomyopathies and heart failure - p. 214 40. Stress echocardiography - p. 218 41. Valvular heart disease (see Part VIII) - p. 220 42. Pericardial disease (see Chapter 86) - p. 233 43. Diseases of the aorta (see Chapter 39) - p. 237 44. Pulmonary embolism (see Chapter 79) - p. 241 45. Pulmonary hypertension (see Chapter 80) - p. 243 46. Infective endocarditis (see Chapter 76) - p. 244 47. Systemic diseases and echocardiography - p. 246 48. Cardiac masses (see Chapter 94) - p. 247 49. Adult congenital heart disease (see Chapter 87) - p. 250 50. Transcatheter interventions (see Chapters 70 and 74) - p. 255 51. Future directions - p. 257 52. References - p. 260 53. 15. Chest radiography in cardiovascular disease - p. 262 54. 16. Nuclear cardiology - p. 271 55. 17. Cardiovascular magnetic resonance imaging - p. 307 56. 18. Cardiac computed tomography - p. 329 57. 19. Coronary angiography and intravascular imaging - p. 361 58. 20. Invasive hemodynamic diagnosis of cardiac disease - p. 384 59. 21. Anesthesia and noncardiac surgery in patients with heart disease - p. 409 60. PART IV. Preventive Cardiology - p. 424 61. 22. The vascular biology of atherosclerosis - p. 425 62. 23. Primary prevention of cardiovascular disease - p. 442 63. 24. Systemic hypertension: Mechanisms, diagnosis, and treatment - p. 471 64. 25. Lipoprotein disorders and cardiovascular disease - p. 502 65. 26. Cardiovascular effects of tobacco and nicotine products - p. 517 66. 27. Nutrition and cardiovascular and metabolic diseases - p. 524 67. 28. Obesity and cardiovascular health - p. 539 68. 29. Diabetes and the cardiovascular system - p. 551 69. 30. Comprehensive cardiac rehabilitation - p. 578 70. 31. Integrative approaches to the management of patients with heart disease - p. 583 71. PART V. Atherosclerotic Cardiovascular Disease - p. 588 72. 32. Approach to the patient with chest pain - p. 589 73. 33. Coronary blood flow and myocardial ischemia - p. 600 74. 34. ST-elevation myocardial infarction pathophysiology and clinical evolution - p. 627 75. 35. ST-elevation myocardial infarction: Management - p. 650 76. Limitation of infarct size - p. 651 77. Prehospital management - p. 652 78. Management in the emergency department - p. 653 79. Reperfusion therapy - p. 656 80. Anticoagulant and antiplatelet therapy - p. 661 81. Hospital management - p. 666 82. Hemodynamic disturbances - p. 671 83. Arrhythmias - p. 686 84. Other complications - p. 691 85. Convalescence, discharge, and postmyocardial infarction care - p. 693 86. Timing of hospital discharge after myocardial infarction - p. 693 87. Counseling - p. 693 88. Risk stratification after st-elevation myocardial infarction - p. 693 89. Assessment at hospital discharge - p. 693 90. Prophylactic antiarrhythmic therapy - p. 694 91. Secondary prevention after acute myocardial infarction - p. 694 92. Future perspectives and emerging therapies - p. 699 93. Guideline Highlights: STEMI Management - p. 699 94. References - p. 699.e6 95. References - p. 699.e6 96. 36. Non–ST elevation acute coronary syndromes - p. 700 97. 37. Stable ischemic heart disease - p. 725 98. Magnitude of the problem - p. 725 99. Stable angina pectoris - p. 726 100. Evaluation - p. 728 101. Medical management - p. 736.e2 102. Revascularization approaches in stable ischemic heart disease - p. 751 103. Other manifestations of coronary artery disease - p. 760 104. Future perspectives - p. 763 105. References - p. 764 106. 38. Percutaneous coronary intervention - p. 768 107. 39. Diseases of the aorta - p. 789 108. Normal aorta - p. 789 109. Aortic aneurysms - p. 791 110. Aortic dissection - p. 802 111. Classification - p. 802 112. Cause and pathogenesis - p. 802 113. Clinical manifestations - p. 804 114. Diagnostic techniques - p. 806 115. Selecting an imaging modality - p. 807 116. Integrated diagnostic evaluation and management algorithms - p. 808 117. Long-term management and follow-up - p. 812 118. Aortic dissection variants - p. 813 119. Aortoarteritis syndromes - p. 815 120. Primary tumors of the aorta - p. 815 121. Key messages and future perspectives for the diagnosis and treatment of aortic diseases - p. 817.e1 122. Aortic Disease* - p. 817.e1 123. Pregnancy in patients with aortopathy - p. 817.e13 124. Physical activity and quality of life - p. 817.e16 125. References - p. 817.e16 126. References - p. 817.e16 127. References - p. 817.e16 128. 40. Peripheral artery diseases - p. 818 129. 41. Treatment of noncoronary obstructive vascular disease - p. 840 130. 42. Prevention and management of ischemic stroke - p. 851 131. PART VI. Arrhythmias, Sudden Death, and Syncope - p. 868 132. 43. Approach to the patient with cardiac arrhythmias - p. 869 133. 44. Mechanisms of cardiac arrhythmias - p. 886 134. 45. Genetics of cardiac arrhythmias - p. 912 135. 46. Therapy for cardiac arrhythmias - p. 931 136. 47. Supraventricular tachycardias - p. 969 137. 48. Atrial fibrillation - p. 996 138. 49. Ventricular arrhythmias - p. 1012 139. 50. Bradyarrhythmias and atrioventricular block - p. 1036 140. 51. Pacemakers, conduction system pacing, cardiac resynchronization therapy, and implantable cardioverter-defibrillators - p. 1046 141. 52. Cardiac arrest and sudden cardiac death - p. 1076 142. 53. Hypotension and syncope - p. 1111 143. PART VII. Heart Failure - p. 1122 144. 54. Mechanisms of cardiac contraction and relaxation - p. 1123 145. 55. Pathophysiology of heart failure - p. 1147 146. 56. Clinical assessment of heart failure - p. 1167 147. 57. Diagnosis and management of decompensated heart failure - p. 1180 148. 58. Management of heart failure patients with reduced ejection fraction - p. 1208 149. 59. Heart failure with preserved or mildly reduced ejection fraction - p. 1239 150. 60. The dilated, restrictive, and infiltrative cardiomyopathies - p. 1266 151. 61. Cardiac amyloidosis - p. 1287 152. 62. Hypertrophic cardiomyopathy - p. 1298 153. 63. Myocarditis - p. 1313 154. 64. Cardio-oncology - p. 1328 155. 65. Devices for monitoring and managing heart failure - p. 1343 156. 66. Mechanical circulatory support - p. 1358 157. 67. Cardiac transplantation - p. 1370 158. PART VIII. Diseases of the Heart Valves - p. 1382 159. 68. Aortic valve stenosis - p. 1383 160. 69. Aortic regurgitation - p. 1404 161. 70. Transcatheter aortic valve replacement - p. 1415 162. 71. Mitral stenosis - p. 1428 163. 72. Mitral regurgitation - p. 1439 164. 73. Tricuspid, pulmonic, and multivalvular disease - p. 1457 165. 74. Transcatheter therapies for mitral and tricuspid valvular heart disease - p. 1468 166. 75. Prosthetic heart valves - p. 1479 167. 76. Infective endocarditis - p. 1490 168. 77. Rheumatic fever - p. 1503 169. PART IX. Diseases of the Pericardium and Pulmonary Vascular Bed - p. 1512 170. 78. Pericardial diseases - p. 1513 171. 79. Pulmonary embolism and deep vein thrombosis - p. 1533 172. 80. Pulmonary hypertension - p. 1557 173. 81. Sleep-disordered breathing and cardiac disease - p. 1580 174. PART X. Cardiovascular Disease in Select Populations - p. 1588 175. 82. Endemic and pandemic viral illnesses and cardiovascular disease: Influenza and COVID-19 - p. 1589 176. 83. Cardiovascular abnormalities in HIV-infected individuals - p. 1607 177. 84. Exercise and sports cardiology - p. 1620 178. 85. Cardiovascular disease in women - p. 1629 179. 86. Pregnancy and heart disease - p. 1643 180. 87. Congenital heart disease in the adolescent and adult - p. 1667 181. 88. Heart disease in various populations - p. 1710 182. 89. Cardiovascular disease in older adults - p. 1717 183. 90. Cardiovascular effects of drugs and toxins - p. 1739 184. PART XI. Cardiovascular Disease and Disorders of Other Systems - p. 1748 185. 91. Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease - p. 1749 186. 92. Endocrine disorders and cardiovascular disease - p. 1774 187. 93. Rheumatic diseases and the cardiovascular system - p. 1794 188. 94. Tumors affecting the cardiovascular system - p. 1815 189. 95. Psychiatric and psychosocial aspects of cardiovascular disease - p. 1827 190. 96. Neuromuscular disorders and cardiovascular disease - p. 1839 191. 97. Interface between kidney, metabolic, and cardiovascular diseases - p. 1858 192. 98. Cardiovascular manifestations of autonomic disorders - p. 1879 193. Disclosure index - p. DI-1 194. Index - p. I-1
